Company intelligence / Profile preview

i-SEP

Ownership: Private
Employees: ~45
Development stage: Other

Overview

i‑SEP’s same™ device enables intraoperative collection and separation of both red blood cells and platelets from surgical blood loss. Clinical trials in four French university hospitals demonstrated that the system can recover more than half of lost platelets with over 84% functionality while matching or exceeding standard-of-care for red cell recovery. The technology aims to reduce reliance on donor transfusions, lower costs, improve patient outcomes, and simplify workflow for clinicians

Therapeutic areas: Hematology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Atlanpole Biotherapies competitiveness clusterAtlanpole incubator support

Beyond the preview

Go deeper on i-SEP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on i-SEP.

Explore the full profile